Aluminum, Calcium Or Magnesium Element, Or Compound Containing Patents (Class 424/682)
  • Patent number: 10751343
    Abstract: Nasal compositions, comprising an aqueous solution containing caffeine and/or theobromine in a total concentration of up to about 0.5 percent (w/v) and an aqueous carrier having a pH of about 6-8 and comprising physiologically acceptable salts of sodium, potassium and calcium. The nasal composition when used as a nasal spray or as nasal drops or irrigation fluid is able to clean the nasal passages and to stimulate nasal mucociliary clearance and, in contrast to nasal decongestants, may be used on a daily-basis for a period longer than 5 days.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: August 25, 2020
    Assignees: Innotesto BVBA, Veramed BV
    Inventors: Franciscus Wilhelmus Henricus Maria Merkus, Bart Merkus
  • Patent number: 10617708
    Abstract: The invention provides a method of treating preeclampsia, fetal growth restriction (FGR or IUGR), obesity in pregnancy, post-partum cardiomyopathy (heart failure in mothers), cancer and diabetic retinopathy, cardiomyopathy, myocardial infarction, wet microdegeneration and other disorders where angiogenesis is aberrant either diminished or exacerbated, comprising modulating the activity of micro RNA (miRNA). Also provided are an MiRNA modulator or a combination thereof or functional fragments or homologues thereof for use in the treatment of preeclampsia, fetal growth restriction, obesity in pregnancy, cancer, and diabetic retinopathy, cardiomyocyte infarction, wet microdegeneration as well as other disorder where angiogenesis is aberrant either diminished or exacerbated. Methods of modulating angiogenesis and pharmaceutical compositions using miR-122, miR-374b or inhibitors of miR-152 or miR195 are also provided together with methods of diagnosis using the miRNAs.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: April 14, 2020
    Assignee: ASTON UNIVERSITY
    Inventors: Meng Cai, Keqing Wang, Asif Ahmed
  • Patent number: 10588890
    Abstract: The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The uses of the invention include administration of the disclosed compositions to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 17, 2020
    Assignee: BIOMMUNITY, INC.
    Inventor: Paul G. Emerson
  • Patent number: 10501527
    Abstract: The present invention relates to methods for treating hypercytokinemia and viral infections associated with hypercytokinemia using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: December 10, 2019
    Assignee: Emergo Therapeutics, Inc.
    Inventors: Robin Parish Hyde-DeRuyscher, Nancy Harlan Hyde-DeRuyscher, Elicia Kristine Hyde-DeRuyscher
  • Patent number: 10350233
    Abstract: A composition and method for preventing or treating an olfactory triggered response within a subject. The method includes applying a thixotropic composition to a nasal cavity, the composition including an aqueous carrier and a viscosity agent, the viscosity agent being in the range of about 2.5% to about 15% by weight within the composition, wherein the composition is configured to change from a semi-solid form to a liquid form upon the composition being subjected to a threshold amount of shear stress, and to return to the semi-solid form upon the elimination of the amount of shear stress.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 16, 2019
    Inventors: Joshua D. Levine, Robert A. Levine
  • Patent number: 10201581
    Abstract: Provided are a composition for cooling skin comprising a Phellodendron bark extract, a method of preparing the composition, a skin-improving product comprising the composition and a method of cooling skin by applying the composition to a skin of a subject, wherein the skin needs cooling. The composition prevents a burning sensation in the skin and under the skin and reduces heat generated under the skin and on the skin. The composition includes a Phellodendron bark extract as a main ingredient and further includes an extract of one or more selected from the group consisting of Anemarrhena asphodeloides, Scutellaria baicalensis, Paeonia lactiflora, Dictamnus dasycarpus, Alumen, Dryobalanops aromatic and Mentha arvensis.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 12, 2019
    Assignees: NATURE4 CO., LTD
    Inventor: Yong Kyu Woo
  • Patent number: 10201161
    Abstract: A molluscicidal particle formed of a solid including at least one metallic compound, including at least one metal selected from the group formed by iron, copper, zinc and aluminum, the solid being suitable for use as an ingested poison for harmful molluscs. The solid includes metaldehyde in a proportion which can vary towards the interior of the solid.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: February 12, 2019
    Assignee: DE SANGOSSE
    Inventor: Frederic Mercier
  • Patent number: 9907811
    Abstract: The present invention generally relates to concentrated natamycin suspension formulations for inhibition of fungal growth. Specifically, the present invention relates to stable suspension concentrate formulations comprising from about 25% to about 48% w/w natamycin, from about 0.1% to about 10% w/w of an anionic surfactant selected from the group consisting of polyelectrolyte polymers, modified styrene acrylic polymers, dioctyl sodium sulfosuccinates, sodium salts of naphthalene sulfonates, and combinations thereof, and water. The formulations of the present invention contain natamycin as particles which are on average less than 11 microns in diameter and the formulations have a viscosity of less than 1400 centipoise at 21 degrees Celsius.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: March 6, 2018
    Assignee: VALENT BIOSCIENCES CORPORATION
    Inventors: Zhengyu Huang, Benjamin A. Belkind, Ayyappan Nair, Gregory D. Venburg, Robert Fassel, Yong-Ki Kim
  • Patent number: 9901101
    Abstract: A method for performing selective bacteriostasis of a sulfate-reducing bacterium, the method selectively inhibiting proliferation of the sulfate-reducing bacterium by allowing chelated Al to coexist in an environment where the sulfate-reducing bacterium exists, and a gypsum composition containing calcined gypsum (A) and chelated Al (B), in which the chelated Al (B) is contained in a range of 0.01 to 20 mass parts relative to 100 mass parts of the calcined gypsum (A).
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: February 27, 2018
    Assignee: YOSHINO GYPSUM CO., LTD.
    Inventors: Koichi Suto, Chihiro Inoue, Masato Yamaguchi, Shinichi Miura
  • Patent number: 9872888
    Abstract: The invention relates to the use of one or more nucleotides for improving the heat stability of an aqueous micellar casein composition comprising 6 to 20 g per 100 ml of micellar casein, and having a pH of about 6 to 8. The invention also relates to heat-treated liquid nutritional compositions comprising 6 to 20 g, preferably 9-20 g, of protein per 100 ml of the composition and having a pH of about 6 to 8, in which all or a major part of said protein comprises micellar casein, further comprising one or more nucleotides.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: January 23, 2018
    Assignee: N.V. Nutricia
    Inventors: Esther Jacqueline Petra De Kort, Marcel Minor
  • Patent number: 9763440
    Abstract: Colored clay particles are prepared by the absorption of pigments, such as dyes, on the surface of clays. The surface of the clay can be modified with a surfactant such that a dye can be well bound to the particle's surface to avoid leaching of the dye into water. The colored clay particles can be used to deter insects, such as the Asian Citrus Psyllid (ACP), by coating a plant, such as a citrus plant, with the colored clay particles. The reflectance of the visible and ultraviolet light can be altered by the choice of dyes such that the spectrum visible to the insect deters the insect from the plant.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 19, 2017
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Brij M. Moudgil, Savino C. Musella, Edgardo Etxeberria, Michael E. Rogers, Craig R. Brodersen, Parvesh Sharma
  • Patent number: 9750705
    Abstract: This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 5, 2017
    Assignee: The Regents of the University of California
    Inventors: Gino Cortopassi, Alexey Tomilov
  • Patent number: 9707253
    Abstract: Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: July 18, 2017
    Assignee: Pharmalyte Solutions, LLC
    Inventors: Stephen F. Brandon, Richard A. Okerholm, Thomas J. Legg
  • Patent number: 9610315
    Abstract: Oral pharmaceutical, nutraceutical, health foods and medical device compositions based on polysaccharides from Opuntia Ficus Indica cladodes in combination with other active substances are useful for the prevention or treatment of GERD (Gastro-Esophageal Reflux Disease), gastric esophagitis and related diseases (e.g. dyspepsia, esophagitis, esofageal tumour, gastro-intestinal symptoms, chronic pharyngitis, Barrett's esophagus, esophageal adenocarcinoma, GERD-related pulmonary symptoms).
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: April 4, 2017
    Assignee: BIONAP S.R.L.
    Inventors: Salvatore Munafo', Luisa Rizza
  • Patent number: 9518950
    Abstract: A carbon nanotube-based micron scale chemical sensor or sensor array is provided that enables the remote detection of hydrogen sulfide and other chemicals in a gas stream. The sensor is suitable for use in harsh environments of high temperature and pressure such as those encountered during petrochemical exploration and recovery. Multiplex sensor devices detect two or more chemical agents simultaneously, or they can detect conditions such as pressure, salinity, humidity, pH, or scale-forming ions. Incorporation of read out electronics and an RF signal generator into the sensor device enables it to communicate to a relay station or receiver for 3D mapping or other analysis. Methods are also provided for fabricating the chemical sensor device and using the device for detection.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: December 13, 2016
    Assignee: Northeastern University
    Inventors: Ahmed Busnaina, Yung Joon Jung, Sivasubramanian Somu, Aniket Datar, Young Lae Kim
  • Patent number: 9433596
    Abstract: The present disclosure relates to a composition for treating anxiety disorder, particularly to a pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder such as post traumatic stress disorder or phobia. In accordance with the present disclosure, N-acetyl-L-cysteine can block the renewal of fear memories for a sustained period of time when it was administered during or after an exposure therapy to treat post traumatic stress disorder or phobia.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: September 6, 2016
    Assignee: SNU R&DB FOUNDATION
    Inventors: Suk Woo Choi, Suk Won Lee, Jeong Yeon Kim, Beom Jong Song, In Gie Hong, Sung Mo Park, Ji Hye Kim, Jun Uk Lee, Bo Bae An
  • Patent number: 9387185
    Abstract: The present invention relates to physically-chemically and pharmacokinetically enhanced N?-hydroxy-L-arginine (NOHA) derivatives and a method for producing the NOHA derivatives having enhanced physical-chemical and pharmacokinetic properties according to the invention.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: July 12, 2016
    Assignee: Christian-Albrechts-Universität Zu Kiel
    Inventors: Bernd Clement, Dennis Schade, Jürke Kotthaus
  • Patent number: 9386776
    Abstract: Calcium additives useful for fortifying baked goods, such as bread products, with calcium are disclosed. The calcium additives are particularly useful for fortifying leavened baked goods with calcium. Methods for preparing the calcium additives and using the calcium additives to fortify baked goods are also disclosed. Generally, the calcium additives comprise intimate admixtures calcium carbonate and an acid such as citric acid.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: July 12, 2016
    Assignee: Delavau L.L.C.
    Inventors: Kevin W. Lang, James W. Dibble, Gregory B. Murphy
  • Patent number: 9265824
    Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: February 23, 2016
    Assignee: ALK-Abello A/S
    Inventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Steven Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
  • Patent number: 9241952
    Abstract: The present invention is concerned with synergistic compositions effective in the treatment of diabetes. In particular, the present invention is concerned with synergistic compositions comprising inulin, or a suitable source thereof, and Sulphonylureas used in the treatment of type-2 Diabetes Mellitus (T2DM) and hyperglyacemia.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 26, 2016
    Assignee: OZSTAR THERAPEUTICS PTY LTD
    Inventors: Nick Naser Gorgani, Mahnoosh Afkham
  • Patent number: 9211259
    Abstract: The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: December 15, 2015
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Doron Friedman, Alex Besonov, Dov Tamarkin, Meir Eini
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
  • Publication number: 20150140129
    Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 21, 2015
    Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
  • Publication number: 20150139938
    Abstract: The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 21, 2015
    Applicant: Ohio State Innovation Foundation
    Inventors: Chandan Sen, Cameron Rink, Sashwati Roy, Greg Christoforidis
  • Publication number: 20150140128
    Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 21, 2015
    Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
  • Publication number: 20150132359
    Abstract: Compositions of reducing agents and carriers for producing a stable negative oxidation reduction potential in consumable materials are disclosed and claimed. Compositions of the invention find use in enhancing the hydration and anti-oxidant value of consumable materials such as foods, beverages and cosmetics, for example. Compositions of the invention also find use in water treatment, agricultural and scientific research applications. Methods for using and making the compositions are also within the scope of the invention.
    Type: Application
    Filed: September 7, 2014
    Publication date: May 14, 2015
    Inventor: DUSAN MILJKOVIC
  • Publication number: 20150125537
    Abstract: There is provided a bone filler material comprising a plurality of particles, each particle comprising a biodegradable outer shell and an inner core. There is also provided an implant prepared from the same, methods of using the same and preparing the same.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 7, 2015
    Inventors: Cho Hong James Goh, Pujiang Shi, Hee Kit Wong, Yong Zhang, Sunny Akogwu Abbah, Jun Li
  • Publication number: 20150118173
    Abstract: The invention relates to a formulation comprising caprylic acid ethanolamide and/or capric acid ethanolamide in combination with an aluminium salt and to its use.
    Type: Application
    Filed: March 28, 2013
    Publication date: April 30, 2015
    Applicant: EVONIK INDUSTRIES AG
    Inventors: Mike Farwick, Oliver Springer, Matthias Mentel, Stefan Bergfried
  • Publication number: 20150110758
    Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 23, 2015
    Inventor: Omar M. Amin
  • Publication number: 20150110839
    Abstract: Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Inventors: Stephen F. Brandon, Feng Zhang, Stuart Schoenherr
  • Patent number: 9011934
    Abstract: There is disclosed a formulation of a transdermal skin treatment effective in inhibition of itch sensation. In an embodiment, the formulation includes a solvent mixture of alcohols, glycols and water combined to provide a solubility parameter between 20 Pa0.5 and 40 Pa0.5, the solvent mixture having an average normal boiling temperature of at least 100° C., the solvent mixture having at least 0.04 mols/liter of multivalent cations, the solvent mixture containing at least one local anesthetic, and the solvent mixture having pH exceeding 8.0, with a thixotropic flow characteristic accomplished by an organic gellant. Other embodiments are also disclosed.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: April 21, 2015
    Assignee: SatisPharma, LLC
    Inventor: Ray L. Hauser
  • Patent number: 9011823
    Abstract: Mouth rinses, dentifrices, lozenges, confections, chewing gums, and similar delivery vehicles containing non-toxic soluble calcium are used prior to administration of a fluoride-containing composition to increase the effectiveness of the fluoride therapy. An effective amount of calcium is released into the oral cavity and allowed to penetrate into the oral tissue. Calcium-bound fluoride deposits form in the oral tissue upon subsequent administration of the fluoride-containing composition to provide increased salivary, plaque and oral tissue fluoride concentrations.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: April 21, 2015
    Assignee: ADA Foundation
    Inventors: Gerald L. Vogel, Laurence C. Chow, Shozo Takagi
  • Publication number: 20150104424
    Abstract: Compositions and methods are provided for improving the health of an animal by reducing certain diseases and by binding certain heavy metals that may be unintentionally introduced into the body of the animal from the environment. Compositions and methods are also provided for improving the feed conversion ratio of an animal. In addition, compositions and methods are provided for reducing nitrate pollution in the environment. In one embodiment, the composition may include mastic gum, a mixture of ionic minerals, and optionally an essential amino acid not produced by the animal. The ionic minerals may be derived from water sourced from an inland sea such as the Great Salt Lake, the Dead Sea, or another inland sea. The essential amino acid may be included in the form of a protein. The animal may be a ruminant, poultry, or other animal. Methods are also provided for processing mastic gum.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Joseph Scivoletto, Steven Adelstein
  • Patent number: 9005672
    Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: April 14, 2015
    Assignees: Abbott Cardiovascular Systems Inc., Medical University of South Carolina
    Inventors: Eugene T. Michal, Shubhayu Basu, Alexander J. Sheehy, Francis G. Spinale, Rupak Mukherjee
  • Patent number: 8999307
    Abstract: Compositions and methods are disclosed for imparting water repellency to the hair. The compositions generally comprise a first hydrophobic particulate material having a coefficient of dynamic friction of 0.5 or greater in combination with a second hydrophobic particulate material having a coefficient of dynamic friction less than 0.5.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: April 7, 2015
    Assignee: Avon Products, Inc.
    Inventors: Rahul A. Ranade, Mark S. Garrison, Freda E. Robinson, Giovana A. Sandstrom
  • Publication number: 20150079152
    Abstract: The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 19, 2015
    Inventors: Michael Wuollett, Susan Wuollett
  • Publication number: 20150079201
    Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
  • Patent number: 8980330
    Abstract: Provided is a method that enables a calcium silicate-based material to be produced more efficiently. The method of producing a calcium silicate-based material comprises: (1) a step of obtaining a reaction product by reacting raw materials containing a calcium component, a silicon component and an aluminum component in an aqueous medium; and (2) a step of forming calcium silicate by subjecting the reaction product to hydrothermal treatment.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 17, 2015
    Assignee: Tomita Pharmaceutical Co., Ltd.
    Inventors: Koh Konishi, Yuta Tsumura, Seiki Shinomiya, Masashi Konishi, Yukinori Konishi
  • Publication number: 20150072005
    Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 12, 2015
    Inventor: Joseph P. Habboushe
  • Publication number: 20150072019
    Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 12, 2015
    Inventors: Michaela Kneissel, Vito Gaugnano, Diana Graus Porta, Simon Wöhrle
  • Patent number: 8974834
    Abstract: The present invention provides a kit or article of manufacture comprising as separate components: (a) a polymeric metal astringent; (b) an anionic surfactant; wherein combining component (a) and (b) provides a reaction product of said polymeric metal astringent and said anionic surfactant in form of a precipitate comprising said metal astringent and said anionic surfactant, for use in the preventive and/or therapeutic treatment of hoof or foot disease in cattle and other types of hoofed animals.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: March 10, 2015
    Assignee: Ecolab USA Inc.
    Inventors: Iris C. Beckert, Petra Vogt
  • Publication number: 20150064285
    Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
    Type: Application
    Filed: March 21, 2014
    Publication date: March 5, 2015
    Applicant: Magceutics, Inc.
    Inventors: Guosong LIU, Fei Mao
  • Publication number: 20150050353
    Abstract: Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load of elemental calcium and a conveniently small size. A drug load of about 96% or more is obtained in tablets of the invention that have sufficient mechanical and organoleptic properties.
    Type: Application
    Filed: August 29, 2014
    Publication date: February 19, 2015
    Inventor: Jan Yngvar Piene
  • Patent number: 8956594
    Abstract: Disclosed are dental compositions and methods. In accordance with one embodiment, a dental composition includes calcium, fluorine, which is generally present in the form of fluoride, and phosphate or another stabilizing anion. The composition is stable as against precipitation of calcium fluoride during transport and storage, but is unstable against the precipitation of calcium fluoride in the oral cavity of a human. In many embodiments, the amount of fluoride may be less than the amount of fluoride used in a comparable composition intended for a similar purpose. A dental method comprises applying the composition to the oral cavity of a patient, whereupon calcium fluoride precipitates from the composition.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: February 17, 2015
    Assignee: ADA Foundation
    Inventors: Laurence C. Chow, Shozo Takagi
  • Patent number: 8956664
    Abstract: The present disclosure relates generally to the field of mucositis. More particularly, methods and compositions for treating, ameliorating and/or preventing mucositis are provided by administering a clay to the subject in need.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: February 17, 2015
    Assignee: Salient Pharmaceuticals Incorporated
    Inventor: Richard M. Scruggs
  • Patent number: 8951505
    Abstract: Disclosed are systems, methods, compositions and kits for mineralizing tissue, particularly dental tissue. The methods, compositions and kits may be used to strengthen and prevent weakening of the tissue. For example, the methods, compositions and kits may be used for treating and filling cavities in teeth caused by tooth decay.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: February 10, 2015
    Assignee: Georgia Health Sciences University Rsearch Institute, Inc.
    Inventors: David Henry Pashley, Franklin Chi-Meng Tay
  • Publication number: 20150030703
    Abstract: Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature so that binding of the active agent to the delivery ligand and release of the active agent into the target site are not dependent on enzymatic activity. Methods of using such compositions are also disclosed.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Inventors: Josee Roy, Toya Kimble
  • Patent number: 8940279
    Abstract: Biguanide-preserved precipitated calcium carbonate oral care compositions and methods of manufacture thereof are disclosed.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 27, 2015
    Assignee: Colgate-Palmolive Company
    Inventors: Nilza Shimohirao, Odete Tieko Yamane, Abel Correia, Katrin Costa, Enzo Utima, Andre S. David
  • Publication number: 20150024069
    Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.
    Type: Application
    Filed: October 10, 2014
    Publication date: January 22, 2015
    Inventor: Josee Roy
  • Publication number: 20150023941
    Abstract: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Inventors: David Bagley, Scott Momii, Scott Nagasawa, Herbert T. Nagasawa